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MEDICAL TREATMENT FOR CHRONIC MYELOID
LEUKAEMIA (CML):AVERAGE COST
EFFECTIVENESS RATIOS OF FIRST AND
SECOND LINE TREATMENT
Groot MT1, Ossenkoppele GJ2, Kramer MHH3,
van den Boom G4, Huijgens PC2, Uyl-de Groot CA1
1Erasmus University Rotterdam, Rotterdam, Netherlands; 2VU
Medical Centre, Amsterdam, Netherlands; 3Meander Medical
Centre, Amersfoort, Netherlands; 4Novartis Pharma B.V,
Arnhem, Netherlands
OBJECTIVE: To determine the average cost-effectiveness
ratios of interferon used ﬁrst line and imatinib used
second line in chronic phase CML. METHODS: A
general cost effectiveness analysis was performed. There-
fore, a model consisting of two phases is developed: an
induction phase of eight months, in which newly diag-
nosed patients are treated with two different doses of IFN
or patients refractory to IFN are treated with imatinib,
and a chronic treatment phase where patients are treated
according the result of the induction phase. Costs and
effects are modeled for a maximum of 25 years. Input 
for this model was derived from literature and expert
opinion. Costs are based on real cost prices and tariffs.
RESULTS: Compared to ﬁrst line IFN, treatment with
imatinib second line gives greater quality adjusted life
years (QALYs); 4.98 versus 6.67. Average costs of treat-
ment with 5MIU IFN are €76,969 and with 3MIU IFN
€53,257. For treatment with imatinib the total costs are
€140,765 per patient. Average cost-effectiveness ratios in
the 5MIU IFN group is €15,445 per QALY and €10,687
in the 3MIU IFN group. Using imatinib second line the
average cost-effectiveness ratio is €21,082 per QALY.
CONCLUSION: The addition of imatinib to the treat-
ment options in CML suggests that the costs of treatment
will rise but average survival and quality of life will also
considerably increase. The average costs per QALY are in
our view fully acceptable.
CANCER—Quality of Life/Preference Based
Outcomes
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AGREEMENT OF HEALTH UTILITIES INDEX
SCORES AMONG SURVIVORS OF CANCER IN
CHILDHOOD,THEIR PARENTS AND THEIR
DOCTORS IN URUGUAY
Horsman JR1, Fluchel M2, Furlong W1, Castillo L3, Barr RD4
1McMaster University, Hamilton, ON, Canada; 2University of
Washington, Seattle, WA, USA; 3Hospital Pereira Rossell,
Montivideo, Uruguay; 4Hamilton Health Sciences, Hamilton,
ON, Canada
OBJECTIVES: The study assesses inter-rater agreement
of Health Utilities Index (HUI) measures reported for 103
survivors of cancers in childhood and 98 age-matched
controls (C) in Montevideo, Uruguay. METHODS: The
children completed face-to-face interviewer-administered
HUI health status questionnaires, Spanish language
version. Parents (P) and doctors (D) of the survivors, and
parents of 22 controls completed proxy-assessments.
Inter-rater agreement of HUI3 single-attribute and health-
related quality of life (HRQL) utility scores was assessed
between children and parents, children and doctors, and
parents and doctors using intra-class correlation coef-
ﬁcients (ICC). RESULTS: Agreement results vary by
attribute (vision, hearing, speech, ambulation, dexterity,
emotion, cognition, pain) but most are substantial (ICC
> 0.60). Due to lack of measurement variability, agree-
ment could not be assessed for HUI3 dexterity. As
hypothesized, agreement is generally substantial between
children and parents. ICC for overall HRQL and indi-
vidual attributes vision, hearing, speech, ambulation, cog-
nition, and pain, varying from 0.554 to 0.999 and all are
signiﬁcant at p < 0.0005. There is only slight agreement
(ICC < 0.20) for the highly subjective emotion attribute,
and that is consistent across all pairs of raters. Agreement
between children and doctors, and parents and doctors is
strongest for easily observed attributes, including vision,
hearing, speech and ambulation (p < 0.005), and weakest
for the less observable attributes (pain, cognition and
emotion). CONCLUSIONS: Results indicate that parents
are reliable proxies for assessing overall HRQL of their
children but parents and doctors may not have sufﬁcient
knowledge or insight into the pain, cognitive or emotional
burdens suffered by these young cancer survivors. These
results are consistent with those reported from an
English-language study of survivors of brain tumours 
in childhood in Hamilton, Canada. This consistency
between studies validates both the results and the
Spanish-language translation of the HUI.
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SPECIFIC CHOICES AND EXPENDITURES FOR
HERBAL MEDICINES BY CANCER PATIENTS
Arbuckle R, Leak JA, Roach P, Palmer JL, Hogervorst SL
The University of Texas M.D. Anderson Cancer Center,
Houston,TX, USA
OBJECTIVES: The use of alternative medicine is increas-
ing worldwide with total annual expenditures on herbal
medicine and/or supplements approaching 10 billion
dollars in the US alone. Cancer patients often feel uncom-
fortable discussing the use of herbals. This survey study
was designed to identify the types of herbals used, evalu-
ate the patients’ expectation of results of use, communi-
cation with the physician regarding use, out-of pocket
expenditure and possible correlations between these and
other demographic factors. METHODS: A survey con-
sisting of 17 questions was developed with a list of herbal
medications purchased by the patient. The instrument
was administered with the assistance of a nurse or phar-
macist to 450 patients in the Pre-op and Symptom and
Palliative Care Clinic (SCPC), 300 and 150 respectively.
The type and stage of cancer were retrieved from the
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chart. RESULTS: An equal number of male and female
were enrolled. For those patient using herbals the mean
age for the Pre-op clinic and SCPC was 60 and 55 years,
respectively. Of those taking herbal medication, 41%
indicated they started after their cancer diagnosis.
Overall, 64–74% of patients spent $25 or less per month
with an additional 23–28% spending up to $100 and
3–8% spending over $100. Patients reported taking
herbal medications to cure their disease, feel more in
control, help with conventional therapy, and help control
symptoms. Sixty-six percent of the SCPC group and 70%
of the Pre-op group had informed one of their physicians
of herbal use. There were no statistical correlations
between any of the demographic or other parameters
report in the survey. CONCLUSION: As the use of herbal
medications and other alternative treatments increase for
the cancer population it is important for health care pro-
fessionals to understand their use by the patient and
incorporate these treatments into the patient care plan.
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A WEIGHTED INDEX FORM OF THE FACT-L FOR
USE IN ECONOMIC EVALUATION
Kind P1, Macran S1, Christie A2
1University of York,York, United Kingdom; 2AstraZeneca UK
Ltd, Luton, Bedfordshire, United Kingdom
FACT-L is a 44-item multidimensional measure of quality
of life developed for use in evaluating treatment of lung
cancer. Patients self-rate items on 0 to 4 scale corre-
sponding to “not at all” and “very much”. Regulatory
and other approval bodies increasingly demand prefer-
ence-weighted measures of outcome. For economic analy-
sis it is generally held that such weights should be utilities.
The pressing need for users of condition-speciﬁc measures
such as FACT-L is a scoring system that meets the require-
ments of regulatory and other non-clinical users. This
paper describes the successful completion of that task.
OBJECTIVES: The primary purpose of the study was to
develop a set of weights for converting FACT-L into 
a index measure for use in cost-utility analysis.
METHODS: The descriptive complexity of FACT-L had
been reduced in a preliminary study that resulted in the
identiﬁcation of 10 key items covering the 6 dimensions
of the FACT-L. These were used to deﬁne 2 sets of 10
health states, each presented in a 14-page questionnaire
together with EQ-5D. Health states were valued on a
0–100 scale corresponding to worst-best possible health.
A value for dead was also recorded. A random sample of
4000 individuals was drawn from the Electoral Registers
of England Scotland and Wales who were mailed ques-
tionnaires during September 2002. RESULTS: Four
hundred twenty-ﬁve (11%) returned a completed ques-
tionnaire. Conjoint analysis and OLS regression were
used to estimate the marginal utilities for the 6 FACT-L
dimensions. Decrements for each of the 10 key FACT-L
items were also computed. Utilities for FACT-L health
states range from 0.738 to 0.146. CONCLUSIONS:
Despite the response rates, valuations from a representa-
tive sample of the general population were obtained for
critical FACT-L items enabling a utility-weighted index
score to be derived from patient self-assessments for use
in economic evaluation.
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ASSESSMENT OF PATIENT-REPORTED
OUTCOMES AMONG PATIENTS WITH
PROSTATE CANCER
Law AW1, Gause D2, Raut M2, Sung J2, Glendenning A2,
McKiernan J3
1Duke Clinical Research Institute, Durham, NC, USA;
2Novartis Pharmaceuticals Corporation, East Hanover, NJ,
USA; 3Columbia University, New York, NY, USA
OBJECTIVE: To compare the psychosocial status and
functional limitations in prostate cancer patients with
patients diagnosed with other types of cancer in a
national sample of US adults. METHODS: This study
compared perceived health status, mental health status,
and physical limitations among prostate cancer patients
with patients of other cancers using the 1998 Medical
Expenditure Panel Survey (MEPS). Men over 18 years
reported to have only one type of cancer (ICD-9-CM =
140 to 239) were included in the analysis. Men with 
colorectal cancer or lung cancer and women with breast
cancer were selected for further comparison in the health
and mental health status categories. All analyses used
patient-speciﬁc sampling weights provided by MEPS and
were adjusted for age and number of co-morbid condi-
tions. RESULTS: Approximately 750,000 men were iden-
tiﬁed with prostate cancer and an additional 4.6 million
male patients were identiﬁed with one other type of
cancer. Fewer prostate cancer patients reported having
“excellent” or “very good” health (51%) compared to
patients with other oncology diagnoses (66%). Individu-
als with prostate cancer reported poorer health status
than patients with all other types of cancer (2.9 vs. 2.6,
respectively) and poorer mental health (2.3 vs. 2.1,
respectively). Speciﬁcally, compared to men with colorec-
tal cancer, patients with prostate cancer reported poorer
health and mental health status. Prostate cancer patients
also have an increased odds of requiring assistance with
ADL and IADL (1.22 and 1.26, respectively) than
patients with all other types of cancer. CONCLUSIONS:
Despite a prolonged life expectancy, we found that
prostate cancer has a greater impact on patients’ percep-
tion of health than other types of cancer. Prostate cancer
patients also reported more limitations in functional
ability compared to other types of cancer combined.
These ﬁndings indicate that in addition to identifying
treatments that improve important clinical parameters, an
emphasis should be placed on improving other health
attributes important to prostate cancer patients (e.g.,
quality of life, satisfaction with treatment).
